Malignant Lymphomas Involving Lung and Pleura

  • Francisco Vega


Primary malignant lymphomas represent approximately 0.5 % of all primary neoplasms of the lung. By contrast, secondary involvement of the lung in patients with systemic lymphoma is common. Most of the primary malignant lymphomas are non-Hodgkin’s lymphomas of B-cell lineage and, overall, extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is the most common type. The second most frequent lymphoma of the lung is diffuse large B-cell lymphoma (DLBCL), some of them representing large cell transformation of a previous MALT lymphoma. Hodgkin’s lymphoma rarely occurs in extranodal sites. Other malignant lymphomas that involve lung and pleura are also discussed including distinct entities such as lymphomatoid granulomatosis, primary effusion lymphomas (PEL), and DLBCL associated with chronic inflammation, also known as pyothorax-associated lymphoma (PAL).


Mantle Cell Lymphoma Anaplastic Lymphoma Kinase Malt Lymphoma Anaplastic Large Cell Lymphoma Primary Effusion Lymphoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Papaioannou AN, Watson WL. Primary lymphoma of the lung: an appraisal of its natural history and a comparison with other ­localized lymphomas. J Thorac Cardiovasc Surg. 1965;49:373–87.PubMedGoogle Scholar
  2. 2.
    Berkman N, Breuer R, Kramer MR, Polliack A. Pulmonary involvement in lymphoma. Leuk Lymphoma. 1996;20(3–4):229–37.PubMedGoogle Scholar
  3. 3.
    L’Hoste Jr RJ, Filippa DA, Lieberman PH, Bretsky S. Primary pulmonary lymphomas. A clinicopathologic analysis of 36 cases. Cancer. 1984;54(7):1397–406.PubMedGoogle Scholar
  4. 4.
    Yang HB, Li J, Shen T. Primary anaplastic large cell lymphoma of the lung. Report of two cases and literature review. Acta Haematol. 2007;118(3):188–91.PubMedGoogle Scholar
  5. 5.
    Kim JH, Lee SH, Park J, Kim HY, Lee SI, Park JO, et al. Primary pulmonary non-Hodgkin’s lymphoma. Jpn J Clin Oncol. 2004;34(9):510–4.PubMedGoogle Scholar
  6. 6.
    Sagaert X, De Wolf-Peeters C, Noels H, Baens M. The pathogenesis of MALT lymphomas: where do we stand? Leukemia. 2007;21(3):389–96.PubMedGoogle Scholar
  7. 7.
    Richmond I, Pritchard GE, Ashcroft T, Avery A, Corris PA, Walters EH. Bronchus associated lymphoid tissue (BALT) in human lung: its distribution in smokers and non-smokers. Thorax. 1993;48(11):1130–4.PubMedGoogle Scholar
  8. 8.
    Escolar Castellon JD, Escolar Castellon A, Roche Roche PA, Minana Amada C. Bronchial-associated lymphoid tissue (BALT) response to airway challenge with cigarette smoke, bovine ­antigen and anti-pulmonary serum. Histol Histopathol. 1992;7(3):321–8.PubMedGoogle Scholar
  9. 9.
    Gould SJ, Isaacson PG. Bronchus-associated lymphoid tissue (BALT) in human fetal and infant lung. J Pathol. 1993;169(2):229–34.PubMedGoogle Scholar
  10. 10.
    Rangel-Moreno J, Hartson L, Navarro C, Gaxiola M, Selman M, Randall TD. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest. 2006;116(12):3183–94.PubMedGoogle Scholar
  11. 11.
    Tashiro K, Ohshima K, Suzumiya J, Yoneda S, Yahiro M, Sugihara M, et al. Clonality of primary pulmonary lymphoproliferative disorders; using in situ hybridization and polymerase chain reaction for immunoglobulin. Leuk Lymphoma. 1999;36(1–2):157–67.PubMedGoogle Scholar
  12. 12.
    Pabst R, Gehrke I. Is the bronchus-associated lymphoid tissue (BALT) an integral structure of the lung in normal mammals, including humans? Am J Respir Cell Mol Biol. 1990;3(2):131–5.PubMedGoogle Scholar
  13. 13.
    Moyron-Quiroz JE, Rangel-Moreno J, Kusser K, Hartson L, Sprague F, Goodrich S, et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med. 2004;10(9):927–34.PubMedGoogle Scholar
  14. 14.
    Addis BJ, Hyjek E, Isaacson PG. Primary pulmonary lymphoma: a re-appraisal of its histogenesis and its relationship to pseudolymphoma and lymphoid interstitial pneumonia. Histopathology. 1988;13(1):1–17.PubMedGoogle Scholar
  15. 15.
    Isaacson P, Wright DH. Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue. Cancer. 1984;53(11):2515–24.PubMedGoogle Scholar
  16. 16.
    Oh SY, Kim WS, Kim JS, Kim SJ, Kwon HC, Lee DH, et al. Pulmonary marginal zone B-cell lymphoma of MALT type – what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy? Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol. 2010;89(6):563–8.PubMedGoogle Scholar
  17. 17.
    Borie R, Wislez M, Thabut G, Antoine M, Rabbat A, Couderc LJ, et al. Clinical characteristics and prognostic factors of pulmonary MALT lymphoma. Eur Respir J. 2009;34(6):1408–16.PubMedGoogle Scholar
  18. 18.
    Herbert A, Wright DH, Isaacson PG, Smith JL. Primary malignant lymphoma of the lung: histopathologic and immunologic evaluation of nine cases. Hum Pathol. 1984;15(5):415–22.PubMedGoogle Scholar
  19. 19.
    Le Tourneau A, Audouin J, Garbe L, Capron F, Servais B, Monges G, et al. Primary pulmonary malignant lymphoma, clinical and pathological findings, immunocytochemical and ultrastructural studies in 15 cases. Hematol Oncol. 1983;1(1):49–60.PubMedGoogle Scholar
  20. 20.
    Cordier JF, Chailleux E, Lauque D, Reynaud-Gaubert M, Dietemann-Molard A, Dalphin JC, et al. Primary pulmonary lymphomas. A clinical study of 70 cases in nonimmunocompromised patients. Chest. 1993;103(1):201–8.PubMedGoogle Scholar
  21. 21.
    Lee DK, Im JG, Lee KS, Lee JS, Seo JB, Goo JM, et al. B-cell lymphoma of bronchus-associated lymphoid tissue (BALT): CT features in 10 patients. J Comput Assist Tomogr. 2000;24(1):30–4.PubMedGoogle Scholar
  22. 22.
    Wislez M, Cadranel J, Antoine M, Milleron B, Bazot M, Mayaud C, et al. Lymphoma of pulmonary mucosa-associated lymphoid tissue: CT scan findings and pathological correlations. Eur Respir J. 1999;14(2):423–9.PubMedGoogle Scholar
  23. 23.
    Raderer M, Vorbeck F, Formanek M, Osterreicher C, Valencak J, Penz M, et al. Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma. Br J Cancer. 2000;83(4):454–7.PubMedGoogle Scholar
  24. 24.
    Thieblemont C, Berger F, Dumontet C, Moullet I, Bouafia F, Felman P, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood. 2000;95(3):802–6.PubMedGoogle Scholar
  25. 25.
    Du M, Diss TC, Xu C, Peng H, Isaacson PG, Pan L. Ongoing mutation in MALT lymphoma immunoglobulin gene suggests that antigen stimulation plays a role in the clonal expansion. Leukemia. 1996;10(7):1190–7.PubMedGoogle Scholar
  26. 26.
    Tierens A, Delabie J, Pittaluga S, Driessen A, DeWolf-Peeters C. Mutation analysis of the rearranged immunoglobulin heavy chain genes of marginal zone cell lymphomas indicates an origin from different marginal zone B lymphocyte subsets. Blood. 1998;91(7):2381–6.PubMedGoogle Scholar
  27. 27.
    Vinatzer U, Gollinger M, Mullauer L, Raderer M, Chott A, Streubel B. Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3. Clin Cancer Res. 2008;14(20):6426–31.PubMedGoogle Scholar
  28. 28.
    Streubel B, Simonitsch-Klupp I, Mullauer L, Lamprecht A, Huber D, Siebert R, et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia. 2004;18(10):1722–6.PubMedGoogle Scholar
  29. 29.
    Begueret H, Vergier B, Parrens M, Lehours P, Laurent F, Vernejoux JM, et al. Primary lung small B-cell lymphoma versus lymphoid hyperplasia: evaluation of diagnostic criteria in 26 cases. Am J Surg Pathol. 2002;26(1):76–81.PubMedGoogle Scholar
  30. 30.
    Nicholson AG, Wotherspoon AC, Diss TC, Hansell DM, Du Bois R, Sheppard MN, et al. Reactive pulmonary lymphoid disorders. Histopathology. 1995;26(5):405–12.PubMedGoogle Scholar
  31. 31.
    Fishleder A, Tubbs R, Hesse B, Levine H. Uniform detection of immunoglobulin-gene rearrangement in benign lymphoepithelial lesions. N Engl J Med. 1987;316(18):1118–21.PubMedGoogle Scholar
  32. 32.
    Collins RD. Is clonality equivalent to malignancy: specifically, is immunoglobulin gene rearrangement diagnostic of malignant lymphoma? Hum Pathol. 1997;28(7):757–9.PubMedGoogle Scholar
  33. 33.
    Zucca E, Conconi A, Pedrinis E, Cortelazzo S, Motta T, Gospodarowicz MK, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003;101(7):2489–95.PubMedGoogle Scholar
  34. 34.
    de Boer JP, Hiddink RF, Raderer M, Antonini N, Aleman BM, Boot H, et al. Dissemination patterns in non-gastric MALT lymphoma. Haematologica. 2008;93(2):201–6.PubMedGoogle Scholar
  35. 35.
    Ferraro P, Trastek VF, Adlakha H, Deschamps C, Allen MS, Pairolero PC. Primary non-Hodgkin’s lymphoma of the lung. Ann Thorac Surg. 2000;69(4):993–7.PubMedGoogle Scholar
  36. 36.
    Cadranel J, Wislez M, Antoine M. Primary pulmonary lymphoma. Eur Respir J. 2002;20(3):750–62.PubMedGoogle Scholar
  37. 37.
    Kennedy JL, Nathwani BN, Burke JS, Hill LR, Rappaport H. Pulmonary lymphomas and other pulmonary lymphoid lesions. A clinicopathologic and immunologic study of 64 patients. Cancer. 1985;56(3):539–52.PubMedGoogle Scholar
  38. 38.
    Koss MN, Hochholzer L, Nichols PW, Wehunt WD, Lazarus AA. Primary non-Hodgkin’s lymphoma and pseudolymphoma of lung: a study of 161 patients. Hum Pathol. 1983;14(12):1024–38.PubMedGoogle Scholar
  39. 39.
    Li G, Hansmann ML, Zwingers T, Lennert K. Primary lymphomas of the lung: morphological, immunohistochemical and clinical features. Histopathology. 1990;16(6):519–31.PubMedGoogle Scholar
  40. 40.
    Gascoyne RD. Pathologic prognostic factors in diffuse aggressive non-Hodgkin’s lymphoma. Hematol Oncol Clin North Am. 1997;11(5):847–62.PubMedGoogle Scholar
  41. 41.
    Lo Coco F, Ye BH, Lista F, Corradini P, Offit K, Knowles DM, et al. Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin’s lymphoma. Blood. 1994;83(7):1757–9.PubMedGoogle Scholar
  42. 42.
    Otsuki T, Yano T, Clark HM, Bastard C, Kerckaert JP, Jaffe ES, et al. Analysis of LAZ3 (BCL-6) status in B-cell non-Hodgkin’s lymphomas: results of rearrangement and gene expression studies and a mutational analysis of coding region sequences. Blood. 1995;85(10):2877–84.PubMedGoogle Scholar
  43. 43.
    Ladanyi M, Offit K, Jhanwar SC, Filippa DA, Chaganti RS. MYC rearrangement and translocations involving band 8q24 in diffuse large cell lymphomas. Blood. 1991;77(5):1057–63.PubMedGoogle Scholar
  44. 44.
    Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood. 1998;92(9):3152–62.PubMedGoogle Scholar
  45. 45.
    Kawasaki C, Ohshim K, Suzumiya J, Kanda M, Tsuchiya T, Tamura K, et al. Rearrangements of bcl-1, bcl-2, bcl-6, and c-myc in diffuse large B-cell lymphomas. Leuk Lymphoma. 2001;42(5):1099–106.PubMedGoogle Scholar
  46. 46.
    Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354(23):2419–30.PubMedGoogle Scholar
  47. 47.
    Lin P, Medeiros LJ. High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis. Haematologica. 2007;92(10):1297–301.PubMedGoogle Scholar
  48. 48.
    de Mascarel A, Merlio JP, Coindre JM, Goussot JF, Broustet A. Gastric large cell lymphoma expressing cytokeratin but no leukocyte common antigen. A diagnostic dilemma. Am J Clin Pathol. 1989;91(4):478–81.PubMedGoogle Scholar
  49. 49.
    Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2–associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003;101(11):4279–84.PubMedGoogle Scholar
  50. 50.
    Le Gouill S, Talmant P, Touzeau C, Moreau A, Garand R, Juge-Morineau N, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica. 2007;92(10):1335–42.PubMedGoogle Scholar
  51. 51.
    Liebow AA, Carrington CR, Friedman PJ. Lymphomatoid granulomatosis. Hum Pathol. 1972;3(4):457–558.PubMedGoogle Scholar
  52. 52.
    Katzenstein AL, Carrington CB, Liebow AA. Lymphomatoid granulomatosis: a clinicopathologic study of 152 cases. Cancer. 1979;43(1):360–73.PubMedGoogle Scholar
  53. 53.
    Nichols PW, Koss M, Levine AM, Lukes RJ. Lymphomatoid granulomatosis: a T-cell disorder? Am J Med. 1982;72(3):467–71.PubMedGoogle Scholar
  54. 54.
    Lipford Jr EH, Margolick JB, Longo DL, Fauci AS, Jaffe ES. Angiocentric immunoproliferative lesions: a clinicopathologic spectrum of post-thymic T-cell proliferations. Blood. 1988;72(5):1674–81.PubMedGoogle Scholar
  55. 55.
    DeRemee RA, Weiland LH, McDonald TJ. Polymorphic reticulosis, lymphomatoid granulomatosis. Two diseases or one? Mayo Clin Proc. 1978;53(10):634–40.PubMedGoogle Scholar
  56. 56.
    Wilson WH, Kingma DW, Raffeld M, Wittes RE, Jaffe ES. Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b. Blood. 1996;87(11):4531–7.PubMedGoogle Scholar
  57. 57.
    Katzenstein AL, Peiper SC. Detection of Epstein-Barr virus genomes in lymphomatoid granulomatosis: analysis of 29 cases by the polymerase chain reaction technique. Mod Pathol. 1990;3(4):435–41.PubMedGoogle Scholar
  58. 58.
    Guinee Jr D, Jaffe E, Kingma D, Fishback N, Wallberg K, Krishnan J, et al. Pulmonary lymphomatoid granulomatosis. Evidence for a proliferation of Epstein-Barr virus infected B-lymphocytes with a prominent T-cell component and vasculitis. Am J Surg Pathol. 1994;18(8):753–64.PubMedGoogle Scholar
  59. 59.
    Myers JL, Kurtin PJ, Katzenstein AL, Tazelaar HD, Colby TV, Strickler JG, et al. Lymphomatoid granulomatosis. Evidence of immunophenotypic diversity and relationship to Epstein-Barr virus infection. Am J Surg Pathol. 1995;19(11):1300–12.PubMedGoogle Scholar
  60. 60.
    Haque AK, Myers JL, Hudnall SD, Gelman BB, Lloyd RV, Payne D, et al. Pulmonary lymphomatoid granulomatosis in acquired immunodeficiency syndrome: lesions with Epstein-Barr virus infection. Mod Pathol. 1998;11(4):347–56.PubMedGoogle Scholar
  61. 61.
    Jaffe ES, Chan JK, Su IJ, Frizzera G, Mori S, Feller AC, et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol. 1996;20(1):103–11.PubMedGoogle Scholar
  62. 62.
    Koss MN, Hochholzer L, Langloss JM, Wehunt WD, Lazarus AA, Nichols PW. Lymphomatoid granulomatosis: a clinicopathologic study of 42 patients. Pathology. 1986;18(3):283–8.PubMedGoogle Scholar
  63. 63.
    Beaty MW, Toro J, Sorbara L, Stern JB, Pittaluga S, Raffeld M, et al. Cutaneous lymphomatoid granulomatosis: correlation of clinical and biologic features. Am J Surg Pathol. 2001;25(9):1111–20.PubMedGoogle Scholar
  64. 64.
    Patsalides AD, Atac G, Hedge U, Janik J, Grant N, Jaffe ES, et al. Lymphomatoid granulomatosis: abnormalities of the brain at MR imaging. Radiology. 2005;237(1):265–73.PubMedGoogle Scholar
  65. 65.
    Tateishi U, Terae S, Ogata A, Sawamura Y, Suzuki Y, Abe S, et al. MR imaging of the brain in lymphomatoid granulomatosis. AJNR Am J Neuroradiol. 2001;22(7):1283–90.PubMedGoogle Scholar
  66. 66.
    Kapila A, Gupta KL, Garcia JH. CT and MR of lymphomatoid granulomatosis of the CNS: report of four cases and review of the literature. AJNR Am J Neuroradiol. 1988;9(6):1139–43.PubMedGoogle Scholar
  67. 67.
    Bolaman Z, Kadikoylu G, Polatli M, Barutca S, Culhaci N, Senturk T. Migratory nodules in the lung: lymphomatoid granulomatosis. Leuk Lymphoma. 2003;44(1):197–200.PubMedGoogle Scholar
  68. 68.
    Sheehy N, Bird B, O’Briain DS, Daly P, Wilson G. Synchronous regression and progression of pulmonary nodules on chest CT in untreated lymphomatoid granulomatosis. Clin Radiol. 2004;59(5):451–4.PubMedGoogle Scholar
  69. 69.
    Braham E, Ayadi-Kaddour A, Smati B, Ben Mrad S, Besbes M, El Mezni F. Lymphomatoid granulomatosis mimicking interstitial lung disease. Respirology. 2008;13(7):1085–7.PubMedGoogle Scholar
  70. 70.
    Makol A, Kosuri K, Tamkus D, de M Calaca W, Chang HT. Lymphomatoid granulomatosis masquerading as interstitial pneumonia in a 66-year-old man: a case report and review of literature. J Hematol Oncol. 2009;2:39.PubMedGoogle Scholar
  71. 71.
    Guinee Jr DG, Perkins SL, Travis WD, Holden JA, Tripp SR, Koss MN. Proliferation and cellular phenotype in lymphomatoid granulomatosis: implications of a higher proliferation index in B cells. Am J Surg Pathol. 1998;22(9):1093–100.PubMedGoogle Scholar
  72. 72.
    Medeiros LJ, Peiper SC, Elwood L, Yano T, Raffeld M, Jaffe ES. Angiocentric immunoproliferative lesions: a molecular analysis of eight cases. Hum Pathol. 1991;22(11):1150–7.PubMedGoogle Scholar
  73. 73.
    Kwon EJ, Katz KA, Draft KS, Seykora JT, Rook AH, Wasik MA, et al. Posttransplantation lymphoproliferative disease with features of lymphomatoid granulomatosis in a lung transplant patient. J Am Acad Dermatol. 2006;54(4):657–63.PubMedGoogle Scholar
  74. 74.
    Saxena A, Dyker KM, Angel S, Moshynska O, Dharampaul S, Cockroft DW. Posttransplant diffuse large B-cell lymphoma of “lymphomatoid granulomatosis” type. Virchows Arch. 2002;441(6):622–8.PubMedGoogle Scholar
  75. 75.
    Mukhopadhyay S, Katzenstein AL. Biopsy findings in acute pulmonary histoplasmosis: unusual histologic features in 4 cases mimicking lymphomatoid granulomatosis. Am J Surg Pathol. 2010;34(4):541–6.PubMedGoogle Scholar
  76. 76.
    Rao R, Vugman G, Leslie WT, Loew J, Venugopal P. Lymphomatoid granulomatosis treated with rituximab and chemotherapy. Clin Adv Hematol Oncol. 2003;1(11):658–60; discussion 60.PubMedGoogle Scholar
  77. 77.
    Ponzoni M, Ferreri AJ, Campo E, Facchetti F, Mazzucchelli L, Yoshino T, et al. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. J Clin Oncol. 2007;25(21):3168–73.PubMedGoogle Scholar
  78. 78.
    Ponzoni M, Arrigoni G, Gould VE, Del Curto B, Maggioni M, Scapinello A, et al. Lack of CD 29 (beta1 integrin) and CD 54 (ICAM-1) adhesion molecules in intravascular lymphomatosis. Hum Pathol. 2000;31(2):220–6.PubMedGoogle Scholar
  79. 79.
    Pfleger L, Tappeiner J. On the recognition of systematized endotheliomatosis of the cutaneous blood vessels (reticuloendotheliosis? Hautarzt. 1959;10:359–63.PubMedGoogle Scholar
  80. 80.
    Murase T, Nakamura S, Tashiro K, Suchi T, Hiraga J, Hayasaki N, et al. Malignant histiocytosis-like B-cell lymphoma, a distinct pathologic variant of intravascular lymphomatosis: a report of five cases and review of the literature. Br J Haematol. 1997;99(3):656–64.PubMedGoogle Scholar
  81. 81.
    Murase T, Nakamura S, Kawauchi K, Matsuzaki H, Sakai C, Inaba T, et al. An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome. Br J Haematol. 2000;111(3):826–34.PubMedGoogle Scholar
  82. 82.
    Ohno T, Miyake N, Hada S, Hirose Y, Imura A, Hori T, et al. Hemophagocytic syndrome in five patients with Epstein-Barr virus negative B-cell lymphoma. Cancer. 1998;82(10):1963–72.PubMedGoogle Scholar
  83. 83.
    Snyder LS, Harmon KR, Estensen RD. Intravascular lymphomatosis (malignant angioendotheliomatosis) presenting as pulmonary hypertension. Chest. 1989;96(5):1199–200.PubMedGoogle Scholar
  84. 84.
    Chim CS, Choy C, Ooi GC, Chung LP, Wong KK, Liang R. Two unusual lymphomas. Case 2: pulmonary intravascular lymphomatosis. J Clin Oncol. 2000;18(21):3733–5.PubMedGoogle Scholar
  85. 85.
    Jang HJ, Lee KS, Han J. Intravascular lymphomatosis of the lung: radiologic findings. J Comput Assist Tomogr. 1998;22(3):427–9.PubMedGoogle Scholar
  86. 86.
    Nambu A, Kurihara Y, Ichikawa T, Ohkubo S, Onoue M, Oyama T, et al. Lung involvement in angiotropic lymphoma: CT findings. AJR Am J Roentgenol. 1998;170(4):940–2.PubMedGoogle Scholar
  87. 87.
    Walls JG, Hong YG, Cox JE, McCabe KM, O’Brien KE, Allerton JP, et al. Pulmonary intravascular lymphomatosis: presentation with dyspnea and air trapping. Chest. 1999;115(4):1207–10.PubMedGoogle Scholar
  88. 88.
    Kitanaka A, Kubota Y, Imataki O, Ohnishi H, Fukumoto T, Kurokohchi K, et al. Intravascular large B-cell lymphoma with FDG accumulation in the lung lacking CT/(67)gallium scintigraphy abnormality. Hematol Oncol. 2009;27(1):46–9.PubMedGoogle Scholar
  89. 89.
    Kotake T, Kosugi S, Takimoto T, Nakata S, Shiga J, Nagate Y, et al. Intravascular large B-cell lymphoma presenting pulmonary arterial hypertension as an initial manifestation. Intern Med. 2010;49(1):51–4.PubMedGoogle Scholar
  90. 90.
    Takamura K, Nasuhara Y, Mishina T, Matsuda T, Nishimura M, Kawakami Y, et al. Intravascular lymphomatosis diagnosed by transbronchial lung biopsy. Eur Respir J. 1997;10(4):955–7.PubMedGoogle Scholar
  91. 91.
    Demirer T, Dail DH, Aboulafia DM. Four varied cases of intravascular lymphomatosis and a literature review. Cancer. 1994;73(6):1738–45.PubMedGoogle Scholar
  92. 92.
    Yegappan S, Coupland R, Arber DA, Wang N, Miocinovic R, Tubbs RR, et al. Angiotropic lymphoma: an immunophenotypically and clinically heterogeneous lymphoma. Mod Pathol. 2001;14(11):1147–56.PubMedGoogle Scholar
  93. 93.
    Hsiao CH, Su IJ, Hsieh SW, Huang SF, Tsai TF, Chen MY, et al. Epstein-Barr virus-associated intravascular lymphomatosis within Kaposi’s sarcoma in an AIDS patient. Am J Surg Pathol. 1999;23(4):482–7.PubMedGoogle Scholar
  94. 94.
    Vega F, Medeiros LJ, Bueso-Ramos C, Jones D, Lai R, Luthra R, et al. Hepatosplenic gamma/delta T-cell lymphoma in bone marrow. A sinusoidal neoplasm with blastic cytologic features. Am J Clin Pathol. 2001;116(3):410–9.PubMedGoogle Scholar
  95. 95.
    Vega F, Medeiros LJ, Gaulard P. Hepatosplenic and other gammadelta T-cell lymphomas. Am J Clin Pathol. 2007;127(6):869–80.PubMedGoogle Scholar
  96. 96.
    Zhao XF, Sands AM, Ostrow PT, Halbiger R, Conway JT, Bagg A. Recurrence of nodal diffuse large B-cell lymphoma as intravascular large B-cell lymphoma: is an intravascular component at initial diagnosis predictive? Arch Pathol Lab Med. 2005;129(3):391–4.PubMedGoogle Scholar
  97. 97.
    Ferreri AJ, Campo E, Seymour JF, Willemze R, Ilariucci F, Ambrosetti A, et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the “cutaneous variant”. Br J Haematol. 2004;127(2):173–83.PubMedGoogle Scholar
  98. 98.
    Wiltshaw E. The natural history of extramedullary plasmacytoma and its relation to solitary myeloma of bone and myelomatosis. Medicine (Baltimore). 1976;55(3):217–38.Google Scholar
  99. 99.
    Dimopoulos MA, Kiamouris C, Moulopoulos LA. Solitary plasmacytoma of bone and extramedullary plasmacytoma. Hematol Oncol Clin North Am. 1999;13(6):1249–57.PubMedGoogle Scholar
  100. 100.
    Shaikh G, Sehgal R, Mehrishi A, Karnik A. Primary pulmonary plasmacytoma. J Clin Oncol. 2008;26(18):3089–91.PubMedGoogle Scholar
  101. 101.
    Edelstein E, Gal AA, Mann KP, Miller Jr JI, Mansour KA. Primary solitary endobronchial plasmacytoma. Ann Thorac Surg. 2004;78(4):1448–9.PubMedGoogle Scholar
  102. 102.
    Chang CC, Chang YL, Lee LN, Lee YC. Primary pulmonary plasmacytoma with immunoglobulin G/lambda light chain ­monoclonal gammopathy. J Thorac Cardiovasc Surg. 2006;132(4):984–5.PubMedGoogle Scholar
  103. 103.
    Koss MN, Hochholzer L, Moran CA, Frizzera G. Pulmonary plasmacytomas: a clinicopathologic and immunohistochemical study of five cases. Ann Diagn Pathol. 1998;2(1):1–11.PubMedGoogle Scholar
  104. 104.
    Joseph G, Pandit M, Korfhage L. Primary pulmonary plasmacytoma. Cancer. 1993;71(3):721–4.PubMedGoogle Scholar
  105. 105.
    Wise JN, Schaefer RF, Read RC. Primary pulmonary plasmacytoma: a case report. Chest. 2001;120(4):1405–7.PubMedGoogle Scholar
  106. 106.
    Kojima M, Motoori T, Tamaki Y, Igarashi T, Matsumoto M, Shimizu K, et al. Cyclin D1 protein overexpression in extramedullary plasmacytoma: a clinicopathologic study of 11 cases. J Clin Exp Hematop. 2009;49(1):53–6.PubMedGoogle Scholar
  107. 107.
    Bink K, Haralambieva E, Kremer M, Ott G, Beham-Schmid C, de Leval L, et al. Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics. Haematologica. 2008;93(4):623–6.PubMedGoogle Scholar
  108. 108.
    Rush WL, Andriko JA, Taubenberger JK, Nelson AM, Abbondanzo SL, Travis WD, et al. Primary anaplastic large cell lymphoma of the lung: a clinicopathologic study of five patients. Mod Pathol. 2000;13(12):1285–92.PubMedGoogle Scholar
  109. 109.
    Delsol G, Al Saati T, Gatter KC, Gerdes J, Schwarting R, Caveriviere P, et al. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis. Am J Pathol. 1988;130(1):59–70.PubMedGoogle Scholar
  110. 110.
    Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263(5151):1281–4.PubMedGoogle Scholar
  111. 111.
    Morris SW, Naeve C, Mathew P, James PL, Kirstein MN, Cui X, et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin’s lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene. 1997;14(18):2175–88.PubMedGoogle Scholar
  112. 112.
    Vega F, Medeiros LJ. Chromosomal translocations involved in non-Hodgkin lymphomas. Arch Pathol Lab Med. 2003;127(9):1148–60.PubMedGoogle Scholar
  113. 113.
    Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999;93(8):2697–706.PubMedGoogle Scholar
  114. 114.
    Onciu M, Behm FG, Downing JR, Shurtleff SA, Raimondi SC, Ma Z, et al. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. Blood. 2003;102(7):2642–4.PubMedGoogle Scholar
  115. 115.
    Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–6.PubMedGoogle Scholar
  116. 116.
    Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496–504.PubMedGoogle Scholar
  117. 117.
    Colby TV, Hoppe RT, Warnke RA. Hodgkin’s disease at autopsy: 1972–1977. Cancer. 1981;47(7):1852–62.PubMedGoogle Scholar
  118. 118.
    Kern WH, Crepeau AG, Jones JC. Primary Hodgkin’s disease of the lung. Report of 4 cases and review of the literature. Cancer. 1961;14:1151–65.PubMedGoogle Scholar
  119. 119.
    Yousem SA, Weiss LM, Colby TV. Primary pulmonary Hodgkin’s disease. A clinicopathologic study of 15 cases. Cancer. 1986;57(6):1217–24.PubMedGoogle Scholar
  120. 120.
    Radin AI. Primary pulmonary Hodgkin’s disease. Cancer. 1990;65(3):550–63.PubMedGoogle Scholar
  121. 121.
    Kumar R, Sidhu H, Mistry R, Shet T. Primary pulmonary Hodgkin’s lymphoma: a rare pitfall in transthoracic fine needle aspiration cytology. Diagn Cytopathol. 2008;36(9):666–9.PubMedGoogle Scholar
  122. 122.
    Cartier Y, Johkoh T, Honda O, Muller NL. Primary pulmonary Hodgkin’s disease: CT findings in three patients. Clin Radiol. 1999;54(3):182–4.PubMedGoogle Scholar
  123. 123.
    Weiss LM, Chang KL. Molecular biologic studies of Hodgkin’s disease. Semin Diagn Pathol. 1992;9(4):272–8.PubMedGoogle Scholar
  124. 124.
    Brinker MG, Poppema S, Buys CH, Timens W, Osinga J, Visser L. Clonal immunoglobulin gene rearrangements in tissues involved by Hodgkin’s disease. Blood. 1987;70(1):186–91.PubMedGoogle Scholar
  125. 125.
    Joos S, Kupper M, Ohl S, von Bonin F, Mechtersheimer G, Bentz M, et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res. 2000;60(3):549–52.PubMedGoogle Scholar
  126. 126.
    Mottok A, Renne C, Willenbrock K, Hansmann ML, Brauninger A. Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood. 2007;110(9):3387–90.PubMedGoogle Scholar
  127. 127.
    Martin-Subero JI, Gesk S, Harder L, Sonoki T, Tucker PW, Schlegelberger B, et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood. 2002;99(4):1474–7.PubMedGoogle Scholar
  128. 128.
    Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. Mutations in the IkBa gene in Hodgkin’s disease suggest a tumour suppressor role for IkappaBalpha. Oncogene. 1999;18(20):3063–70.PubMedGoogle Scholar
  129. 129.
    Trumper LH, Brady G, Bagg A, Gray D, Loke SL, Griesser H, et al. Single-cell analysis of Hodgkin and Reed-Sternberg cells: molecular heterogeneity of gene expression and p53 mutations. Blood. 1993;81(11):3097–115.PubMedGoogle Scholar
  130. 130.
    Rushin JM, Riordan GP, Heaton RB, Sharpe RW, Cotelingam JD, Jaffe ES. Cytomegalovirus-infected cells express Leu-M1 antigen. A potential source of diagnostic error. Am J Pathol. 1990;136(5):989–95.PubMedGoogle Scholar
  131. 131.
    Sheibani K, Battifora H, Burke JS, Rappaport H. Leu-M1 antigen in human neoplasms. An immunohistologic study of 400 cases. Am J Surg Pathol. 1986;10(4):227–36.PubMedGoogle Scholar
  132. 132.
    Wieczorek R, Burke JS, Knowles 2nd DM. Leu-M1 antigen expression in T-cell neoplasia. Am J Pathol. 1985;121(3):374–80.PubMedGoogle Scholar
  133. 133.
    Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med. 2007;357(19):1916–27.PubMedGoogle Scholar
  134. 134.
    Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood. 1996;88(2):645–56.PubMedGoogle Scholar
  135. 135.
    Horenstein MG, Nador RG, Chadburn A, Hyjek EM, Inghirami G, Knowles DM, et al. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi’s ­sarcoma-associated herpesvirus/human herpesvirus-8. Blood. 1997;90(3):1186–91.PubMedGoogle Scholar
  136. 136.
    Dukers NH, Rezza G. Human herpesvirus 8 epidemiology: what we do and do not know. AIDS. 2003;17(12):1717–30.PubMedGoogle Scholar
  137. 137.
    Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332(18):1186–91.PubMedGoogle Scholar
  138. 138.
    Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995;86(4):1276–80.PubMedGoogle Scholar
  139. 139.
    Dupin N, Diss TL, Kellam P, Tulliez M, Du MQ, Sicard D, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000;95(4):1406–12.PubMedGoogle Scholar
  140. 140.
    Knowles DM, Inghirami G, Ubriaco A, Dalla-Favera R. Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and the possible pathogenetic role of the Epstein-Barr virus. Blood. 1989;73(3):792–9.PubMedGoogle Scholar
  141. 141.
    Carbone A, Gaidano G. HHV-8-positive body-cavity-based lymphoma: a novel lymphoma entity. Br J Haematol. 1997;97(3):515–22.PubMedGoogle Scholar
  142. 142.
    Schulz TF. Epidemiology of Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8. Adv Cancer Res. 1999;76:121–60.PubMedGoogle Scholar
  143. 143.
    Morassut S, Vaccher E, Balestreri L, Gloghini A, Gaidano G, Volpe R, et al. HIV-associated human herpesvirus 8-positive primary lymphomatous effusions: radiologic findings in six patients. Radiology. 1997;205(2):459–63.PubMedGoogle Scholar
  144. 144.
    Said W, Chien K, Takeuchi S, Tasaka T, Asou H, Cho SK, et al. Kaposi’s sarcoma-associated herpesvirus (KSHV or HHV8) in primary effusion lymphoma: ultrastructural demonstration of herpesvirus in lymphoma cells. Blood. 1996;87(12):4937–43.PubMedGoogle Scholar
  145. 145.
    Wang HY, Fuda FS, Chen W, Karandikar NJ. Notch1 in primary effusion lymphoma: a clinicopathological study. Mod Pathol. 2010;23(6):773–80.PubMedGoogle Scholar
  146. 146.
    Said JW, Shintaku IP, Asou H, de Vos S, Baker J, Hanson G, et al. Herpesvirus 8 inclusions in primary effusion lymphoma: report of a unique case with T-cell phenotype. Arch Pathol Lab Med. 1999;123(3):257–60.PubMedGoogle Scholar
  147. 147.
    Beaty MW, Kumar S, Sorbara L, Miller K, Raffeld M, Jaffe ES. A biophenotypic human herpesvirus 8 – associated primary bowel lymphoma. Am J Surg Pathol. 1999;23(8):992–4.PubMedGoogle Scholar
  148. 148.
    Ansari MQ, Dawson DB, Nador R, Rutherford C, Schneider NR, Latimer MJ, et al. Primary body cavity-based AIDS-related lymphomas. Am J Clin Pathol. 1996;105(2):221–9.PubMedGoogle Scholar
  149. 149.
    Luan SL, Boulanger E, Ye H, Chanudet E, Johnson N, Hamoudi RA, et al. Primary effusion lymphoma: genomic profiling revealed amplification of SELPLG and CORO1C encoding for proteins important for cell migration. J Pathol. 2010;222(2):166–79.PubMedGoogle Scholar
  150. 150.
    Cesarman E, Mesri EA, Gershengorn MC. Viral G protein-coupled receptor and Kaposi’s sarcoma: a model of paracrine neoplasia? J Exp Med. 2000;191(3):417–22.PubMedGoogle Scholar
  151. 151.
    Nakatsuka S, Yao M, Hoshida Y, Yamamoto S, Iuchi K, Aozasa K. Pyothorax-associated lymphoma: a review of 106 cases. J Clin Oncol. 2002;20(20):4255–60.PubMedGoogle Scholar
  152. 152.
    Simonelli C, Spina M, Cinelli R, Talamini R, Tedeschi R, Gloghini A, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol. 2003;21(21):3948–54.PubMedGoogle Scholar
  153. 153.
    Boulanger E, Gerard L, Gabarre J, Molina JM, Rapp C, Abino JF, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol. 2005;23(19):4372–80.PubMedGoogle Scholar
  154. 154.
    Halfdanarson TR, Markovic SN, Kalokhe U, Luppi M. A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy. Ann Oncol. 2006;17(12):1849–50.PubMedGoogle Scholar
  155. 155.
    An J, Sun Y, Fisher M, Rettig MB. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia. 2004;18(10):1699–704.PubMedGoogle Scholar
  156. 156.
    Klass CM, Krug LT, Pozharskaya VP, Offermann MK. The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood. 2005;105(10):4028–34.PubMedGoogle Scholar
  157. 157.
    Iuchi K, Ichimiya A, Akashi A, Mizuta T, Lee YE, Tada H, et al. Non-Hodgkin’s lymphoma of the pleural cavity developing from long-standing pyothorax. Cancer. 1987;60(8):1771–5.PubMedGoogle Scholar
  158. 158.
    Fukayama M, Ibuka T, Hayashi Y, Ooba T, Koike M, Mizutani S. Epstein-Barr virus in pyothorax-associated pleural lymphoma. Am J Pathol. 1993;143(4):1044–9.PubMedGoogle Scholar
  159. 159.
    Martin A, Capron F, Liguory-Brunaud MD, De Frejacques C, Pluot M, Diebold J. Epstein-Barr virus-associated primary malignant lymphomas of the pleural cavity occurring in longstanding pleural chronic inflammation. Hum Pathol. 1994;25(12):1314–8.PubMedGoogle Scholar
  160. 160.
    Androulaki A, Drakos E, Hatzianastassiou D, Vgenopoulou S, Gazouli M, Korkolopoulou P, et al. Pyothorax-associated lymphoma (PAL): a western case with marked angiocentricity and review of the literature. Histopathology. 2004;44(1):69–76.PubMedGoogle Scholar
  161. 161.
    Yamato H, Ohshima K, Suzumiya J, Kikuchi M. Evidence for local immunosuppression and demonstration of c-myc amplification in pyothorax-associated lymphoma. Histopathology. 2001;39(2):163–71.PubMedGoogle Scholar
  162. 162.
    Narimatsu H, Ota Y, Kami M, Takeuchi K, Suzuki R, Matsuo K, et al. Clinicopathological features of pyothorax-associated lymphoma; a retrospective survey involving 98 patients. Ann Oncol. 2007;18(1):122–8.PubMedGoogle Scholar
  163. 163.
    Das DK, Gupta SK, Ayyagari S, Bambery PK, Datta BN, Datta U. Pleural effusions in non-Hodgkin’s lymphoma. A cytomorphologic, cytochemical and immunologic study. Acta Cytol. 1987;31(2):119–24.PubMedGoogle Scholar
  164. 164.
    Vega F, Padula A, Valbuena JR, Stancu M, Jones D, Medeiros LJ. Lymphomas involving the pleura: a clinicopathologic study of 34 cases diagnosed by pleural biopsy. Arch Pathol Lab Med. 2006;130(10):1497–502.PubMedGoogle Scholar
  165. 165.
    Olson PR, Silverman JF, Powers CN. Pleural fluid cytology of Hodgkin’s disease: cytomorphologic features and the value of immunohistochemical studies. Diagn Cytopathol. 2000;22(1):21–4.PubMedGoogle Scholar
  166. 166.
    Bernardeschi P, Bonechi I, Urbano U. Recurrent pleural effusion as manifesting feature of primitive chest wall Hodgkin’s disease. Chest. 1988;94(2):424–6.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Hematopathology, Unit 72The University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations